

ASX Announcement

Investor webinar – Azer-cel trial update

SYDNEY, Australia, 3 September 2024: Imugene Limited (ASX:IMU), a clinical-stage immuno- oncology company, is pleased to announce it will hold an investor webinar on **Wednesday 4 September 2024 at 10am AEST** to discuss the new data from its azer-cel Phase 1b clinical trial in blood cancer Diffuse Large B-Cell Lymphoma (announced 2 September 2024).

Presenting as part of the webinar will be Imugene's Managing Director and CEO Leslie Chong, alongside Chief Medical Officer Dr Paul Woodard.

Shareholders, investors and other interested parties are encouraged to register for the webinar at the following link:

https://us02web.zoom.us/webinar/register/WN_8wAd4wMOS-uGeiz2jJ_yYQ

After registering, you will receive a confirmation email with details on how to join the webinar.

A recording will be available at the same link shortly after the conclusion of the session.

Investors are encouraged to send questions prior to the webinar to matt@nwrcommunications.com.au

For more information please contact:

Leslie Chong
Managing Director and Chief Executive Officer
info@imugene.com

General Investor Enquiries
shareholderenquiries@imugene.com

Media Enquiries
Matt Wright
matt@nwrcommunications.com.au



U.S Investor Enquiries

Heather Armstrong

harmstrong@imugene.com

Connect with us on LinkedIn @Imugene Limited

Follow us on Twitter @TeamImugene

Watch us on YouTube @ImugeneLimited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer Imugene Limited.